Creative Biolabs Expands Preclinical Platforms for CNS and Gene Therapy Research

Creative Biolabs announced the expansion of its in vivo pharmacology capabilities on March 21, 2026, with an upgraded rodent behavioral profiling platform designed specifically for central nervous system research. The enhanced platform offers highly standardized evaluations of both cognitive and motor functions to help reduce the translational gap in the development of therapeutics for neurodegenerative diseases.

The clinical attrition rate for CNS therapeutics remains historically high, frequently due to the lack of predictive preclinical models that accurately reflect complex human neuropathology. The upgraded platform aims to address this challenge by providing a more holistic efficacy profile for pipeline candidates, integrating cognitive and neuromuscular assessments to better capture the nuanced, multifaceted progression of neurodegeneration.

The enhanced platform offers a robust suite of comprehensive rodent behavioral tests for cognition, utilizing industry-standard paradigms such as the Morris Water Maze, Novel Object Recognition, and Y-Maze to quantitatively evaluate spatial learning, working memory, and recognition. Simultaneously, the company provides advanced assessments of rodent motor function, incorporating automated Rotarod tests, grip strength measurements, and open-field locomotor tracking to detect subtle therapeutic improvements or neurotoxicities in motor coordination, balance, and muscle endurance.

The director of in vivo pharmacology stated that the predictive validity of any CNS animal model relies heavily on the sensitivity and reproducibility of the behavioral assays applied, and that integrating these dual-assessment platforms has successfully supported multiple IND applications for novel neuroprotective agents.

Separately, Creative Biolabs announced on February 17, 2026, the expansion of its circRNA and nucleic acid analysis platforms as circRNA rapidly emerges as one of the most promising modalities in modern gene therapy. Researchers are seeking partners capable of delivering high‑purity constructs, scalable manufacturing, and rigorous analytical validation. The upgraded platforms directly address these needs, offering end‑to‑end support from early discovery to preclinical development.

Circular RNAs have gained substantial attention due to their exceptional stability, long half‑life, and reduced immunogenicity compared with linear mRNA. These properties make circRNAs highly attractive for long‑term protein expression, vaccine development, and next‑generation RNA therapeutics. Creative Biolabs' circRNA service platform provides rational design, high‑yield in vitro transcription, post‑transcriptional circularization, and ultra‑high‑purity QC pipelines, enabling researchers to move efficiently from concept to functional therapeutic candidates.

A senior scientist stated that the circRNA platform was built to eliminate bottlenecks that slow therapeutic development, and that from optimized IRES selection to scalable GMP‑compliant production, every construct is engineered for performance, purity, and regulatory readiness. One customer from a European biotech described the experience as "exceptionally collaborative," adding that the circRNA constructs performed consistently across in vitro and in vivo models and saved weeks of troubleshooting.

In addition to custom services, Creative Biolabs offers a broad catalog of circRNA products designed for biomarker research, therapeutic target validation, vaccine development, and drug delivery studies. These products feature flexible synthesis scales, customizable base modifications, and multiple ligation strategies—including enzymatic, chemical, and ribozyme‑based circularization—to meet diverse research needs. CircRNA products can be tailored for tissue‑specific expression, enhanced stability, or reduced immunogenicity, supporting research across oncology, cardiovascular disease, and neurological disorders.

To complement its circRNA platforms, Creative Biolabs provides a full suite of nucleic acid analysis services, ensuring identity, concentration, purity, potency, and safety of nucleic acid materials. These analytical capabilities—spanning LC‑MS/MS, NGS, UV absorbance, qPCR, HPLC, endotoxin testing, and immunogenicity assessment—form a critical foundation for high‑quality gene therapy development. The company's analytical lead stated that reliable analytical data is essential for every stage of nucleic acid‑based therapeutics, and that the integrated testing framework helps clients de‑risk development and meet stringent regulatory expectations.

With its expanded offerings, Creative Biolabs positions itself as a single‑source partner for researchers developing RNA‑based therapeutics. The company's scientific expertise, customizable workflows, and commitment to quality enable clients to streamline development timelines and generate high‑confidence data packages for downstream studies.